Related Experiment Video
Updated: Jul 16, 2026
08:45
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Genetic determinants of statin intolerance
Jisun Oh1, Matthew R Ban, Brooke A Miskie
1Schulich School of Medicine and Dentistry, University of Western Ontario and Vascular Biology Research Group, Robarts Research Institute, London, Ontario, Canada. jisun.oh@utoronto.ca
Lipids in Health and Disease
|March 23, 2007
Summary
Genetic variations in the COQ2 gene are linked to statin intolerance, particularly muscle symptoms. This suggests the Coenzyme Q10 pathway may play a role in how individuals respond to statin medications.
Area of Science:
- Pharmacogenetics
- Molecular biology
- Genetics
Background:
- Statin medications can cause a spectrum of muscle disorders, from mild aches to severe myopathy.
- The genetic underpinnings of statin-induced muscle problems remain largely uncharacterized.
- Previous research links COQ2 gene mutations to inherited myopathies, suggesting a potential role in statin intolerance.
Purpose of the Study:
- To investigate the association between common genetic variations in the COQ2 gene and statin intolerance.
- To explore the potential role of the Coenzyme Q10 (CoQ10) pathway in statin-related muscle symptoms.
Main Methods:
- A case-control study involving 133 patients with statin-induced myopathy and 158 matched controls who tolerated statins.
- Genotyping was performed using two single nucleotide polymorphisms (SNP1 and SNP2) and a 2-SNP haplotype analysis of the COQ2 gene.
Main Results:
- Significant associations were found between COQ2 genotypes (SNP1, SNP2, and the 2-SNP haplotype) and statin intolerance.
- Homozygotes for rare alleles of SNP1, SNP2, and the 2-SNP haplotype showed increased odds ratios for statin intolerance (2.42, 2.33, and 2.58, respectively).
Conclusions:
- Preliminary findings suggest that genomic variations in COQ2 are associated with statin intolerance, especially muscle-related symptoms.
- These results support the hypothesis that the CoQ10 pathway may influence individual responses to statin therapy.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...